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http://www.biomedcentral.com/1472-6963/14/419RESEARCH ARTICLE Open AccessCost-effectiveness analysis of liraglutide versus
sitagliptin or exenatide in patients with
inadequately controlled Type 2 diabetes on oral
antidiabetic drugs in Greece
Charalampos Tzanetakos1*, Andreas Melidonis2, Christos Verras2, Georgia Kourlaba3 and Nikos Maniadakis1Abstract
Background: To evaluate the long-term cost-effectiveness of liraglutide versus sitagliptin or exenatide, added to
oral antidiabetic drug mono- or combination therapy respectively, in patients with Type 2 diabetes in Greece.
Methods: The CORE Diabetes Model, a validated computer simulation model, was adapted to the Greek healthcare
setting. Patient and intervention effects data were gathered from a clinical trial comparing liraglutide 1.2 mg once daily
vs. sitagliptin 100 mg once daily, both combined with metformin, and a clinical trial comparing liraglutide 1.8 mg once
daily vs. exenatide 10 μg twice daily, both as add-on to metformin, glimepiride or both. Direct costs were reported in
2013 Euros and calculated based on published and local sources. All future outcomes were discounted at 3.5% per
annum, and the analysis was conducted from the perspective of a third-party payer in Greece.
Results: Over a patient’s lifetime, treatment with liraglutide 1.2 mg vs. sitagliptin drove a mean increase in discounted
life expectancy of 0.13 (SD 0.23) years and in discounted quality-adjusted life expectancy of 0.19 (0.16) quality-adjusted
life years (QALYs), whereas therapy with liraglutide 1.8 mg vs. exenatide yielded increases of 0.14 (0.23) years and 0.19
(0.16) QALYs respectively. As regards lifetime direct costs, liraglutide 1.2 mg resulted in greater costs of €2797 (€1468)
versus sitagliptin, and so did liraglutide 1.8 mg compared with exenatide (€1302 [€1492]). Liraglutide 1.2 and 1.8 mg
doses were associated with incremental cost effectiveness ratios of €15101 and €6818 per QALY gained, respectively.
Conclusions: Liraglutide is likely to be a cost-effective option for the treatment of Type 2 diabetes in a Greek setting.
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Type 2 diabetes mellitus (T2DM) is a complex multifac-
torial chronic progressive disease that is spread world-
wide over the past three decades, making it a public
health menace [1]. Accounting for approximately 90% of
all diabetes cases, T2DM is shown to be associated with
increased morbidity and mortality resulting in consider-
able socioeconomic implications for national healthcare
systems [2]. In Greece, following the prevalence patterns
of other developed countries, the prevalence of T2DM
among adults was estimated at 7.6% in men and 5.9% in* Correspondence: tzanet.haris@gmail.com
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article, unless otherwise stated.women [3]. According to International Diabetes Federation
(IDF), the diabetes-related deaths among Greek patients
aged between 20–79 years old mounted to 4906 in 2013
[4]. Furthermore, the average annual cost of treatment for
a patient with T2DM in Greece was recently gauged at
€1297.30 and could rise up to €2889 considering the cost
of hospitalizations due to disease micro- and macrovascu-
lar complications (2.3 billion Euros or 12% of total health-
care expenditure) [5].
Current treatment recommendations advocate the use
of lifestyle interventions (diet and exercise) and metformin
as first-line therapy, with the subsequent stepwise addi-
tions of an oral agent (sulphonylurea, thiazolidinedione or
dipeptidyl peptidase-4 [DPP-4] inhibitor), a glucagon-like
peptide 1 (GLP-1) receptor agonist or an insulin (usuallytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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on patient and drug characteristics, with the overarching
goal of improving glycaemic control while minimizing side
effects [6].
In light of drug characteristics, head-to-head clinical trial
data from large, controlled studies have displayed the
higher or comparable safety and efficacy of liraglutide, a
longer-acting GLP-1 analogue, in terms of glycated haemo-
globin (HbA1c) reduction, reductions in body weight, and
the drug’s low hypoglycaemic event rates compared with
other anti-hyperglycaemic agents from various antidiabetic
classes such as sitagliptin, exenatide and basal insulin [8].
Hence, the multifactorial clinical profile of liraglutide has
been well established and, makes it a good candidate for
the treatment of patients with T2DM failing first-line anti-
hyperglycaemic therapy based on the current disease man-
agement guidelines [6].
Nonetheless, an antihyperglycaemic treatment may be an
effective and safe option for T2DM, but it also imposes a
tangible cost to the healthcare payers. The balance of treat-
ment efficacy and costs should be examined to maximize
value for money in healthcare spending. The aim of this
study was to investigate the cost-effectiveness of liraglu-
tide versus sitagliptin or exenatide respectively, as adjunct
treatments to oral antidiabetic drug (OAD) therapy,




The present cost-effectiveness analysis was conducted
using the CORE Diabetes Model (CDM) in order to pro-
ject the long-term clinical and cost outcomes associated
with liraglutide and its comparators. A detailed descrip-
tion of the model’s design and operational features has
been published elsewhere [9,10]. The CDM is an Internet-
based computer simulation model developed to deter-
mine the long-term health outcomes (life expectancy,
quality-adjusted life expectancy, cumulative incidences
of complications) and economic consequences (annual
and cumulative costs per patient, costs associated with
complications and treatment), as well as incremental cost-
effectiveness ratios (ICER) of interventions in type 1
and type 2 diabetes. The model is a validated [9] non-
product-specific, diabetes policy analysis tool that performs
real-time simulations taking into account the baseline
population characteristics, history of complications, vari-
ous screening and treatment strategies for micro-vascular
complications, treatment strategies for end-stage compli-
cations, as well as other multi-factorial interventions. Dis-
ease progression relies upon a series of inter-dependent
Markov sub-models that simulate progression of disease
related complications (angina, myocardial infarction,
congestive heart failure, stroke, peripheral vascular disease,diabetic retinopathy, macula oedema, cataract, hypoglycaemia,
ketoacidosis, nephropathy and end-stage renal disease,
neuropathy, foot ulcer, amputation, depression, and non-
specific mortality). Each sub-model uses time, state and
diabetes type-dependent probabilities derived from pub-
lished sources and utilizes tracker variables to overcome
the memory-less properties of standard Markov models,
allowing interconnectivity and interaction between indi-
vidual complication sub-models.
Simulated cohorts and treatment effects
For the comparison of liraglutide versus sitagliptin 100 mg
once daily, both as add-on to metformin monotherapy, a
patient cohort was defined with baseline demographics,
baseline complications and physiological parameters rep-
resentative of the patients enrolled in the respective treat-
ment arms of the randomized head-to-head clinical trial
(1860 Study Group) after being poorly controlled with
metformin alone [11]. The chosen dose for liraglutide was
1.2 mg once daily following common clinical practice in
Greece (standard dose). As regards the treatment com-
parison of liraglutide versus exenatide, baseline patient
cohort characteristics were elicited from the Liraglutide
Effect and Action in Diabetes 6 (LEAD 6) randomized
head-to-head clinical trial in which patients, inadequately
controlled on metformin, sulfonylurea, or both, were
assigned to receive additional liraglutide 1.8 mg once daily
or exenatide 10 μg BID [12]. Note the dose-escalation of
liraglutide from 1.2 mg to 1.8 mg was preserved in the
model analysis since no clinical data was available for
1.2 mg dose. A subgroup of patients (65%) was assumed
to take also glimepiride in conjunction with metformin.
Furthermore, a cohort reflective of typical Greek patients
was considered and inserted in the sensitivity analysis of
liraglutide versus sitagliptin or exenatide, with data ex-
tracted from Liatis et al. study [13] and other local sources
(Table 1). Where input data were missing, data from 1860
clinical trial were encompassed. All simulated cohorts are
shown in Table 1.
Treatment effects for both simulations of liraglutide
vs. sitagliptin and liraglutide vs. exenatide were derived
directly from the aforementioned clinical trials. These
effects were applied in the first year of the modelling
simulation, while their long-term progression was mod-
elled by relying upon published studies incorporated in
the CDM [10] and assumptions. A summary of treat-
ment effects and their long-term progression is given in
Table 2. Regarding the assumptions, HbA1c effect was
assumed to be sustained over model simulations for
both treatment arms. Duration of incretin-based therap-
ies was set to 5 years, after which basal insulin therapy
was initiated in an attempt to replicate clinical practice
(OADs therapy was maintained). Further, it was assumed
that body mass index (BMI) was affected during the
Table 1 Baseline patients’ characteristics of 1860, LEAD-6 and Greek simulated cohorts
1860 LEAD-6 Greek*
Patient demographics
Baseline age (years) 55.3 (9.2) 56.7 (10.3) 64.5 (10.5)
Duration of diabetes (years) 6 (5.1) 8.2 (6) 10.4 (8.3)
Percentage male 52.9% 51.9% 51.5%
Baseline risk factors
HbA1c (%) 8.4 (0.8) 8.2 (1.0) 8.2 (1.8)
Systolic blood pressure (mmHg) 132.2 (14.5) 133.0 (16.6) 139.8 (19.3)
Total cholesterol (mmol/l) 4.79 (0.38) 4.7 (0.95) 5.5 (−)
HDL (mmol/l) 1.16 (0.31) 1.2 (0.3) 1.2 (0.3)
LDL (mmol/l) 2.65 (0.82) 2.95 (0.8) 3.7 (1.0)
Triglycerides (mmol/l) 2.38 (2.22) 2.15 (1.35) 1.9 (1.4)
Body mass index (kg/m2) 32.8 (5.2) 32.9 (5.7) 30.4 (5.3)
Proportion smoker¶ 36.0% 36.0% 36.0%
Cigarettes per day¶ 18.7 18.7 18.7
Alcohol consumption (Oz/week)¶ 15.91 15.91 15.91
Racial characteristics
Proportion White 90% 80.6% 100%
Proportion Black 7.5% 5.5% 0%
Proportion Hispanic 0% 12.4% 0%
Proportion Native American 0.5% 1.3% 0%
Proportion Asian/Pacific Islander 2% 0.2% 0%
Baseline CVD complications
Proportion with myocardial infarction 2.7% 2.6% 12.8%
Proportion with angina 1.8% 1.9% 5.0%
Proportion with peripheral vascular disease 0.9% 0.6% 5.6%
Proportion with stroke 0.8% 0.2% 8.1%
Proportion with congestive heart failure 0.4% 1.5% 4.2%
Proportion with atrial fibrillation 1.5% 1.5% 9.1%
Proportion with left ventricular hypertrophy 0.2% 0.2% 3.1%
Baseline renal complications
Proportion with microalbuminuria 1.1% 1.1% 1.1%
Proportion with gross proteinuria 0.2% 0.2% 0.2%
Proportion with end-stage renal disease 0.4% 0.6% 0.4%
Baseline retinopathy complications
Proportion with BDR 2.7% 1.1% 25%
Proportion with PDR 0.2% 0.2% 4%
Proportion with severe vision loss 0.4% 0.6% 4.5%
Baseline macular edema
Proportion with macular edema 1.1% 0.2% 1.1%
Baseline cataract
Proportion with cataract 1.7% 6.9% 1.7%
Baseline foot ulcer complications
Prop. uninfected ulcer 0.6% 0.2% 0.6%
Prop. infected ulcer 0.3% 0.0% 0.3%
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Table 1 Baseline patients’ characteristics of 1860, LEAD-6 and Greek simulated cohorts (Continued)
Prop. healed ulcer 0.0% 0.0% 0.0%
Prop. history of amputation 0.0% 0.2% 0.0%
Baseline neuropathy
Proportion with neuropathy 11.6% 7.8% 14.7%
Baseline depression
Proportion with depression† 0% 0% 9%
Data are mean (SD). *In the Greek cohort, all demographic and physiological parameters were retrieved from S. Liatis et al. study [13], while the renal, foot ulcer,
macular oedema and cataract complications values were assumed to be the same as for 1860 cohort. All other diabetes-related complications were taken from
National School of Public health (data on file) and racial characteristics from Hellenic Statistical Authority (www.statistics.gr). ¶Considering all cohorts, the smoking
status and number of cigarettes per day were elicited from National School of Public health, Healthcare map 2011 (data on file), whereas the alcohol consumption
estimate from S. Liatis et al. study [13]. †Proportion with depression assumed to be 0 in 1860 and LEAD-6 cohorts. Liraglutide Effect and Action in Diabetes 6 = LEAD-6;
HbA1c = glycated haemoglobin; HDL = high-density lipoprotein; LDL = low-density lipoprotein; CVD = cardiovascular disease; BDR = background diabetic retinopathy;
PDR = proliferative diabetic retinopathy.
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ing treatment switching. Major and minor hypoglycaemic
rates were based on 1860 and LEAD-6 trials [11,12] for
the first 5 years of simulation, and on LEAD-5 trial [14]
for the remainder of model duration.
Costs and utilities
The present analysis was conducted from a third-party
payer perspective (National Organisation for Healthcare
Services Provision [EOPYY]) and only direct healthcare
costs were included in the model (Table 3). The daily
drug costs were calculated by combining the daily dose
of antihyperglycaemic agents, as retrieved from the
corresponding clinical trials and validated by two autho-
rized local diabetologist experts reflecting also current
medical practice in Greece, with the drug unit costs pro-
vided by the most recent price bulletin issued by the
Greek Ministry of Health [15] in conjunction with the
internal reference price system attached to the latestTable 2 Summary of treatment effects: 1860 and LEAD-6 trial






Change from baseline in HbA1c (%) −1.24 1.04 −0.90
Change from baseline in SBP (mm Hg) −0.55 13.23 −0.94
Change from baseline in total cholesterol (mmol/l) −0.03 0.82 −0.02
Change from baseline in LDL (mmol/l) 0.08 0.69 0.13
Change from baseline in HDL (mmol/l) 0.00 0.17 0.00
Change from baseline in triglycerides (mmol/l) −0.19 1.42 −0.40
Change from baseline in BMI (kg/m2) −1.00 0.08 −0.34
Major hypoglycaemia (events per 100 patient-years) 1.00 0.00
Minor hypoglycaemia (events per 100 patient-years) 17.80 10.60
*P between treatment arms < 0.001 for change in HbA1c and BMI. ¶P between treat
triglycerides and minor hypoglycaemic events. #Long-term hypoglycaemic event ra
study [14]. HbA1c = glycated haemoglobin; BMI = body mass index; LDL = low-densi
UKPDS = United Kingdom Prospective Diabetes Study; SD = standard deviation.published positive drug list. More specifically, the drug unit
costs were based on the social security reimbursement
prices minus the patient co-payment, a rebate of 9% im-
posed upon manufacturers to get into the positive drug list
and another rebate based on volume which can be up to
8% depending on quarterly sales (law 4052/2012, Govern-
ment Gazette). Finally, a conservative 5% volume-related
rebate was considered on top of the 9%. Apart from anti-
hyperglycaemic medication costs, the direct healthcare
costs also reflected and encapsulated thoroughly the
resource consumption incurred for the management of
patients with diabetes and their developed complications.
In particular, costs associated with patients’ hospitalization,
outpatient visits, screening, concomitant medication,
laboratory tests and management of hypoglycaemic events
were considered (Table 3). All cost data were reported in
2013 values (€). Data for resource utilization for the man-
agement of T2DM and its complications were retrieved
from diabetologist experts’ opinion. In addition, wheres & long-term progression approach








SD Mean SD Mean SD
1.04 −1.12 1.22 −0.79 1.22 No HbA1c creep assumption
13.17 −2.51 17.55 −2.00 17.93 UKPDS progression
0.80 −0.20 1.02 −0.09 1.01 Framingham progression
0.68 −0.44 0.84 −0.40 0.84 Framingham progression
0.17 −0.04 0.23 −0.05 0.23 Framingham progression
1.38 −0.41 1.50 −0.23 1.48 Framingham progression
0.08 −1.15 1.35 −1.02 1.47 Constant after returning to baseline
0.00 2.00 0.00#
193.20 260.00 128.70#
ment arms < 0.0001 for change in HbA1c and P < 0.05 for change in
tes were based on the Liraglutide Effect and Action in Diabetes 5 (LEAD-5)
ty lipoprotein; HDL = high density lipoprotein; SBP = Systolic blood pressure;
Table 3 Health state, event, drug acquisition and consumable costs used in the analysis, expressed in 2013 Euros (€)
Cost description Costs (€) Reference
Management costs
Annual cost of statins 147.97 Experts opinion & Drug price bulletin [15]
Annual cost of aspirin 14.41 Experts opinion & Drug price bulletin [15]
Annual cost of ACE inhibitors 78.32 Experts opinion & Drug price bulletin [15]
Annual cost of screening for microalbuminuria 8.66 Government Gazette*
Annual cost of screening for gross proteinuria 8.66 Government Gazette*
Annual cost of stopping ACEIs due to side effects 15.00 Experts opinion
Annual cost of eye screening 10.00 Experts opinion & Government Gazette¶
Annual cost of foot screening program 10.00 Experts opinion & Government Gazette¶
Annual cost of non-standard ulcer treatment 0.00 This is a patient’s expenditure
Annual cost of anti-depression treatment 154.50 Experts opinion & Drug price bulletin [15]
Annual cost of screening for depression 10.00 Experts opinion & Government Gazette¶
Direct costs of cardiovascular complications
Myocardial infarction, 1st year of event 6000 G. Kourlaba et al. [19]
Myocardial infarction, each subsequent year 1964 G. Kourlaba et al. [19]
Angina, 1st year of event 3613 National School of Public Health (data on file)
Angina, each subsequent year 1197 National School of Public Health (data on file)
Congestive heart failure, year of onset 3910 National School of Public Health (data on file)
Congestive heart failure, each subsequent year 1398 National School of Public Health (data on file)
Stroke, 1st year of event 4406 G. Kourlaba et al. [19]
Stroke, each subsequent year 1976 G. Kourlaba et al. [19]
Stroke, death within 30 days 3675 Government Gazette† (DRG-code: N30Mα)
& G. Kourlaba et al. [19]
Peripheral vascular disease, year of onset 5713 G. Kourlaba et al. [20]
Peripheral vascular disease, each subsequent year 1426 G. Kourlaba et al. [20]
Direct costs of renal complications
Hemodialysis, first year 40352 D. Kaitelidou et al. & K. Souliotis et al. [17,18]
Hemodialysis, each subsequent year 40352 Assumed equal with 1st year hemodialysis cost
Peritoneal dialysis, first year 46156 Experts opinion & Government Gazette†
(DRGs-code: Υ28Α and Y02M)
Peritoneal dialysis, each subsequent year 43656 Experts opinion & Government Gazette†
(DRG-code: Υ28Α)
Kidney transplant, first year 18489 S. Sidiropoulos [21]
Kidney transplant, each subsequent year 5400 K. Souliotis et al. [17]
Direct costs of acute events
Major hypoglycaemic event 700 National School of Public Health (data on file)
Minor hypoglycaemic event 250 National School of Public Health (data on file)
Direct costs of eye disease
Cost of laser treatment 731 Government Gazette† (DRG-code: O03A)
Cost of cataract operation 933 Government Gazette† (DRG-code: O15A)
Cost following cataract operation 59 Experts opinion & Drug price bulletin [15]
Cost of blindness in year of onset 11280 Experts opinion & K. Athanasakis et al. [16]
Cost of blindness in subsequent years 6200 Experts opinion & K. Athanasakis et al. [16]
Direct costs of neuropathy, foot ulcer and amputation
Neuropathy, year of onset 1120 Experts opinion, Drug price bulletin [15]
& Government Gazette¶‡
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Table 3 Health state, event, drug acquisition and consumable costs used in the analysis, expressed in 2013 Euros (€)
(Continued)
Neuropathy, each subsequent year 1120 Experts opinion, Drug price bulletin [15]
& Government Gazette¶‡
Amputation, year of event 6629 Government Gazette† (DRG-code: K11M)
Amputation, prosthesis 1150 Government Gazette‡
Gangrene treatment 5282 Experts opinion, Drug price bulletin [15] &
Government Gazette† (DRGs-code: K11M & K13M)
Cost of infected ulcer treatment 2835 Experts opinion, Drug price bulletin [15] &
Government Gazette¶† (DRG-code: Δ20Μ)
Cost of uninfected ulcer treatment 387 Experts opinion, Drug price bulletin [15]
& Government Gazette¶
Cost after healed ulcer 120 Experts opinion & Government Gazette¶
Cost of healed ulcer (history of amputation) 1471 Government Gazette† (DRG-code: Δ20Χ)
Costs of interventions Drug price bulletin [15]
Liraglutide (1.2 mg) 3.44 per day
Liraglutide (1.8 mg) 5.16 per day
Sitagliptin 1.30 per day
Exenatide BID 2.84 per day
Metformin 0.11 per day
Sulphonylurea (Glimepiride) 0.14 per day
Basal insulin (Glargine) 1.38 per day
Consumable costs Government Gazette#
Needles for injectable drugs 0.17 per needle
SMBG test strips 0.43 per strip
SMBG lancets 0.09 per lancet
*Reimbursement for screening tests (Ministerial Decree, Α4 /2878/4-6-1992).
¶Reimbursement for a doctor’s office visit (Presidential Decree, FEK 262A’/16-12-2011).
†Reimbursement for diagnosis-related groups (Common Ministerial Decree, FEK 946B’/27-3-2012).
‡EOPYY Health Provision Policy Regulation (Common Ministerial Decree, FEK 3054B’/18-11-2012).
#Reimbursement for consumables (Common Ministerial Decree, FEK 1561B’/21-06-2013).
ACE = Angiotensin-converting enzyme; SMBG = Self-monitoring blood glucose, DRG = Diagnosis-related group.
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published studies or other local sources [16-21] and cost
data, not available in 2013 values, were inflated using the
corresponding health inflation rates reported by the
National Statistical Service [22]. Moreover, unit price
data were obtained from the “Government Gazette”,
as well as from data on file maintained by the National
School of Public Health. Health state utility and event
disutility values were the same as for an older cost-
effectiveness analysis of liraglutide versus sitagliptin in
the UK setting [23].
Cost-effectiveness analysis
A non-parametric bootstrapping approach was employed
for this health economic analysis. After running 1000 sim-
ulations over a cohort of 1000 non-identical patients gen-
erated with mean and standard deviation (SD) values,
1000 bootstrap samples were drawn. For each bootstrap
iteration, the progression of diabetes was simulated inthe patient cohort, to calculate mean (SD) costs, life
expectancy and quality-adjusted life expectancy [10]. The
results from the bootstrapped simulations were used to
generate acceptability curves. Although there is no official
willingness-to-pay threshold for Greece, a treatment was
considered to be cost-effective at a threshold of €34000
per quality-adjusted life year (QALY) gained. This is based
on the World Health Organisation (WHO) guidelines
that state that a treatment should be considered cost-
effective if the ICER is between 1 or 3 times the Gross
Domestic Product (GDP) per capita of that country
and a treatment is considered highly cost-effective at
less than 1 times the GDP per capita [24]. Using current
prices, the International Monetary Fund (IMF) esti-
mated Greek GDP per capita at €17000 [25]. In the base
case, quality-adjusted life expectancy and future costs
were discounted at a rate of 3.5% annually which is
the standard practice in Greece [26] and simulations
were run over patients’ lifetimes.
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Univariate sensitivity analyses were performed for both
treatment comparisons (1000 bootstrap iterations for each
scenario) in order to evaluate the key drivers and robust-
ness of the base case cost-effectiveness results. Specifically,
individual parameters such as discount rate, cost of com-
plications and treatment duration, were varied between
low and high values within plausible ranges, whereas time
horizon parameter was tested in a series of lower than
base case values. In respect of parameters like disutility of
major and minor hypoglycaemic events, values were
removed or set all to one distinct value (−0.0052), as used
in the National Institute for Health and Care Excellence
(NICE) technology appraisal of insulin glargine [27]. For
physiological parameters such as treatment effects in
HbA1c, systolic blood pressure (SBP), blood lipids and
BMI, the reported upper and lower 95% confidence inter-
val (CI) in clinical trials for liraglutide arm were applied in
the analyses. Further, the BMI benefit was assumed to be
preserved after dropping incretin-based therapy. New pa-
rameters’ data were also tested via employing the United
Kingdom Prospective Diabetes Study (UKPDS) progres-
sion equation for the first five years of the simulation or
the Greek cohort characteristics instead of baseline
patients’ characteristics from the clinical trials. Under the
same rationale, as part of the follow-up to the 1860 clin-
ical trial, one year clinical data for liraglutide vs. sitagliptin
were also examined as well as a new treatment path
involving a switch from sitagliptin to liraglutide after one
year based on the 52- and 78-week extension studies,
respectively [28,29]. Last, in an attempt to compare exena-
tide with 1.2 mg liraglutide, we used the price of the
1.2 mg dose and ran scenarios with efficacy set to 100%,
90%, 80% and 70% of the 1.8 mg dose. This approach is
based on observed values in LEAD1-4 studies [8], where
the clinical effectiveness of liraglutide 1.2 mg found to be





Compared with sitagliptin, liraglutide resulted in mean in-
creases in discounted life expectancy and quality-adjusted
life expectancy of 0.13 years (SD 0.23) and 0.19 QALYs
(0.16) respectively, and was also correlated with greater
lifetime health expenditures (€2797 [SD 1468]). Moreover,
liraglutide was accompanied with lower cumulative inci-
dence rates of long-term complications such as myocar-
dial infarction, stroke and amputation (liraglutide: 17.16%,
8.79%, and 10.06% vs. sitagliptin: 17.83%, 9.24% and
10.54% respectively; Table 4). Considering both liraglutide
and sitagliptin treatment arms, the largest component of
lifetime direct costs was the drug acquisition costs,accounting for 38.13% versus 30.60% of total costs re-
spectively, while the second largest comprised of the ac-
crued ulcer, amputation and neuropathy costs (16.86% vs.
19.42% respectively). Based on the aforementioned health
and cost outcomes, an ICER of €15101 per QALY gained
was estimated for liraglutide (Table 5). The probability
of liraglutide 1.2 mg being a cost-effective therapeutic
option at a willingness-to-pay threshold of €30000 per
QALY gained was above 70% (72.5%) (Figure 1).
Liraglutide vs. exenatide
In comparison with exenatide, mean increases in dis-
counted life expectancy and quality-adjusted life expect-
ancy of 0.14 years (SD 0.23) and 0.19 QALYs (0.16) were
associated with liraglutide 1.8 mg over a patient’s lifetime.
These clinical benefits were endorsed by the reduced cu-
mulative incidence of diabetes-related complications noted
in the liraglutide arm (Table 4). Relating to the lifetime dir-
ect costs, liraglutide maintained a more costly profile and
was connected with higher mean costs of €1302 (SD 1492)
with major cost contributor being again the drug acquisi-
tion costs (proportion of total costs: 42.80% for liraglutide
vs. 35.60% for exenatide). The second most significant cost
driver remained the costs related to the diabetic foot and
neuropathy complications (13.55% for liraglutide vs.
35.60% for exenatide). The ICER of liraglutide versus exe-
natide was estimated at €6818 per QALY gained (Table 5).
At a willingness-to-pay threshold of €30000 per QALY
gained, liraglutide was found to be the accepted interven-
tion in over 83.2% of cases (Figure 1).
Sensitivity analyses
Liraglutide vs. sitagliptin and liraglutide vs. exenatide
As depicted in Table 6, simulation results were quite sensi-
tive to the gradual shortening of model time horizon
resulting in an increase of base case ICER for liraglutide
1.2 mg by more than 600% at 5 years simulation. Neverthe-
less, it should be stressed that liraglutide maintained its
cost-effective profile when time horizon was set to 30 and
20 years under a willingness-to-pay of €34000 per QALY
gained. Setting the discount rate to 0 a lower ICER was
traced in favour of liraglutide 1.2 mg, while in the opposite
direction of increasing it to 6% the corresponding ICER
augmented. In the sensitivity scenario of rising or dimin-
ishing the base case values of all complication costs by 10
percent, no major changes in ICERs of liraglutide 1.2 mg
were observed. On the contrary, simulation results were
quite sensitive to patients’ HbA1c values underlining, as
such, the importance of this biochemical parameter to
health and cost outcomes of model analysis. In fact, the
upper and lower 95% CI limits of the liraglutide 1.2 mg ef-
fect in HbA1c were associated with quite higher and lower
ICERs respectively. When HbA1c was assumed to follow
the UKPDS creep, the respective ICER grew more than
Table 4 Cumulative incidence of long-term complications for liraglutide, sitagliptin and exenatide BID*
Complication Liraglutide 1.2 mg Sitagliptin Difference Liraglutide 1.8 mg Exenatide BID Difference
Eye disease, %
Background retinopathy 17.18 (1.26) 19.26 (1.29) −2.08 18.64 (1.24) 20.91 (1.27) −2.27
Proliferative retinopathy 0.51 (0.22) 0.67 (0.27) −0.15 0.61 (0.25) 0.78 (0.27) −0.17
Severe vision loss 6.78 (0.76) 7.51 (0.83) −0.73 6.59 (0.78) 7.46 (0.86) −0.87
Macular edema 13.59 (1.11) 15.44 (1.14) −1.85 12.95 (1.04) 14.88 (1.08) −1.93
Cataract 10.62 (0.96) 11.11 (1.02) −0.49 10.27 (1.02) 10.85 (1.05) −0.58
Renal disease, %
Microalbuminuria 24.22 (1.35) 27.02 (1.44) −2.80 28.95 (1.43) 31.87 (1.55) −2.92
Gross proteinuria 5.07 (0.71) 6.38 (0.78) −1.30 6 (0.78) 7.26 (0.81) −1.26
End-stage renal disease 0.58 (0.23) 0.83 (0.29) −0.26 0.65 (0.26) 0.90 (0.3) −0.26
Diabetic foot & neuropathy, %
Foot ulcer 30.91 (1.42) 32.97 (1.48) −2.07 28.36 (1.35) 30.21 (1.4) −1.85
Amputation 10.06 (1.05) 10.54 (1.01) −0.48 8.63 (0.98) 9.13 (1.01) −0.51
Neuropathy 47.51 (1.75) 52.27 (1.69) −4.76 45.74 (1.61) 50.13 (1.71) −4.39
Cardiovascular disease, %
Congestive heart failure 13.23 (1.05) 14.29 (1.08) −1.06 13.54 (1.09) 14.31 (1.15) −0.78
Peripheral vascular disease 9.34 (0.90) 10.82 (1) −1.49 8.69 (0.88) 10.43 (0.94) −1.73
Angina 13.01 (1.11) 13.52 (1.11) −0.51 12.05 (1.02) 12.87 (1.08) −0.82
Stroke 8.79 (0.95) 9.24 (0.91) −0.46 8.69 (0.94) 9.45 (0.92) −0.76
Myocardial infarction 17.16 (1.19) 17.83 (1.22) −0.68 16.31 (1.17) 17.55 (1.25) −1.24
Hypoglycaemia, %
Major hypoglycaemia 0.11 (0.01) 0 (0) 0.11 0 (0) 0.22 (0.02) −0.22
Minor hypoglycaemia 23.63 (0.48) 22.88 (0.45) 0.75 31.66 (0.50) 34.49 (0.46) −2.84
*Values shown are mean (SD) cumulative incidences over patient lifetimes from the base case modelling simulation expressed as a percentage of patients
experiencing events.
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tide 1.2 mg was not preserved. Changes in other physio-
logical measures, as well as utility decrements attached to
hypoglycaemic events, had leaner impact on the liraglutide
1.2 mg ICERs. In the Greek cohort analysis, although a
quite elevated ICER (increased by 61.3%) was traced, yet
liraglutide 1.2 mg continued to be a cost-effective option at
the defined willingness-to-pay threshold. Likewise, when
we varied the length of liraglutide treatment between 3
and 7 years towards replicating a real-life setting the cost-
effective profile of liraglutide treatment was retained. 52-
week clinical data were associated with an ICER reduced
by 30%, while switching patients to liraglutide after 1 year
of sitagliptin treatment demonstrated a greater ICER
noting a 32.2% increase. Last, comparing liraglutide 1.2 mg
with exenatide showed that the liraglutide treatment is the
dominant strategy in all efficacy scenarios. As regards lira-
glutide 1.8 mg, similar trends were found (Table 6).
Discussion
Long-term projections suggested that once daily doses of
1.2 and 1.8 mg of liraglutide treatment result in greaterimprovements in life-expectancy and quality-adjusted life
expectancy, as well as reduced incidence rates of diabetes-
related complications compared with once daily 100 mg
sitagliptin or twice daily 10 μg exenatide, respectively.
From a third-party perspective (EOPYY), evaluation of
cost-effectiveness based on quality-adjusted life expect-
ancy of 1.8 and 1.2 mg liraglutide doses generated ICERs
varying from €6818 to €15101 per QALY gained, re-
spectively. These ICERs, in fact, lie below the thresh-
old of €34000 per QALY gained and, thus, liraglutide
1.2 mg combined with metformin monotherapy and
liraglutide 1.8 mg combined with metformin and sul-
phonylurea are found to be highly cost-effective strat-
egies for the treatment of T2DM versus sitagliptin or
exenatide, respectively. In the base case analysis, lira-
glutide treatment was associated with higher direct
medical costs over patients’ lifetime, mainly due to
increased drug acquisition costs. However, these were
partially curbed by the cost savings marked in the
treatment of diabetes-related complications due to
the lower risk of unfolding these complications with
liraglutide therapy.
Table 5 Health and economic outcomes (ICERs) of the base case analyses
Liraglutide 1.2 mg Sitagliptin Difference
Discounted life expectancy (years) 14.22 (0.18) 14.09 (0.17) 0.13 (0.23)
Discounted quality-adjusted life expectancy (QALYs) 9.24 (0.12) 9.05 (0.11) 0.19 (0.16)
Discounted total lifetime direct medical costs (€) 39524 (1100) 36727 (1113) 2797 (1468)
Drug acquisition 15069 11240 3829
Patient management* 1939 1928 11
Cardiovascular disease 5858 6170 −312
Renal disease 1146 1253 −107
Diabetic foot and neuropathy 6665 7132 −467
Eye disease 5325 5676 −351
Hypoglycaemia 3522 3329 193
ICER (€ per QALY gained) 15101
Liraglutide 1.8 mg Exenatide BID Difference
Discounted life expectancy (years) 14.10 (0.17) 13.96 (0.16) 0.14 (0.23)
Discounted quality-adjusted life expectancy (QALYs) 9.22 (0.12) 9.03 (0.11) 0.19 (0.16)
Discounted total lifetime direct medical costs (€) 43236 (1049) 41934 (1065) 1302 (1492)
Drug acquisition 18505 14927 3578
Patient management* 1931 1920 11
Cardiovascular disease 5544 5980 −436
Renal disease 1611 1692 −81
Diabetic foot and neuropathy 5859 6317 −458
Eye disease 4461 4948 −487
Hypoglycaemia 5326 6149 −823
ICER (€ per QALY gained) 6818
Values shown are means with SDs in parentheses. *Concomitant medication and screening. QALY = quality-adjusted life year; € = 2013 Euros; ICER = incremental
cost-effectiveness ratio.
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cost-effectiveness analyses have been focused on com-
paring liraglutide with sitagliptin or exenatide. Based on
the results of the present analysis, we reach similar con-
clusions as these previous evaluations where liraglutide
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Figure 1 Cost effectiveness acceptability curves of liraglutide vs. sitagthe reported willingness-to-pay thresholds, from a health-
care payer perspective. In specific, regarding the liraglutide
1.2 mg versus sitagliptin comparison, Lee et al. [30] calcu-
lated an ICER of $25742/QALY gained for the former
treatment in the United States (US), while in the United




liptin (red line) and liraglutide vs. exenatide (blue line).
Table 6 Summary of results of the sensitivity analyses









ICER [€ per QALY gained]
Base case 0.19 (0.16) 2797 (1468) 15101 0.19 (0.16) 1302 (1492) 6818
Model time horizon:
30 years 0.18 (0.15) 2857 (1428) 15767 0.18 (0.15) 1380 (1541) 7874
20 years 0.12 (0.11) 2946 (1186) 23797 0.12 (0.12) 1531 (1218) 12531
10 years 0.06 (0.06) 3569 (791) 61595 0.05 (0.06) 2306 (774) 43977
5 years 0.04 (0.02) 3787 (452) 106618 0.03 (0.03) 2458 (516) 84503
Discount rate:
0% 0.34 (0.31) 2319 (2759) 6776 0.36 (0.30) 552 (2767) 1529
6% 0.13 (0.11) 2879 (1057) 22353 0.13 (0.11) 1529 (1081) 11754
Costs of complications:
Increased by 10% 0.19 (0.16) 2694 (1605) 14541 0.19 (0.16) 1074 (1630) 5625
Decreased by 10% 0.19 (0.16) 2902 (1323) 15666 0.19 (0.16) 1531 (1355) 8020
Physiological parameters:
HbA1c 95% upper limit 0.23 (0.15) 2411 (1565) 10334 0.26 (0.16) 798 (1500) 3101
HbA1c 95% lower limit 0.14 (0.16) 3270 (1557) 23725 0.12 (0.16) 1947 (1500) 15961
UKPDS creep of HbA1c for 5 years 0.10 (0.15) 3362 (1597) 32756 0.10 (0.15) 1922 (1613) 18940
SBP 95% upper limit 0.20 (0.16) 2784 (1517) 14086 0.21 (0.15) 1142 (1500) 5380
SBP 95% lower limit 0.18 (0.15) 2897 (1468) 16246 0.19 (0.15) 1375 (1444) 7327
Lipid 95% upper limit 0.22 (0.16) 2744 (1541) 12693 0.22 (0.15) 1162 (1605) 5373
Lipid 95% lower limit 0.17 (0.16) 2781 (1492) 16577 0.16 (0.15) 1459 (1525) 9400
BMI 95% upper limit 0.20 (0.15) 2810 (1500) 13823 0.20 (0.17) 1274 (1484) 6231
BMI 95% lower limit 0.18 (0.16) 2820 (1500) 16030 0.18 (0.16) 1269 (1460) 7263
BMI benefit maintained 0.25 (0.15) 2759 (1476) 11105 0.21 (0.16) 1312 (1492) 6408
Hypoglycaemia:
No hypo disutility 0.19 (0.16) 2797 (1468) 14867 0.18 (0.16) 1302 (1492) 7272
Disutility of −0.0052 for all hypos 0.19 (0.16) 2797 (1468) 15118 0.19 (0.16) 1302 (1492) 6699
Treatment duration:
7 years 0.20 (0.15) 3941 (1428) 19773 0.20 (0.17) 2114 (1557) 10458
3 years 0.19 (0.17) 1329 (1500) 7123 0.19 (0.16) 275 (1460) 1480
Greek cohort data 0.12 (0.14) 3008 (1775) 24355 0.12 (0.15) 1586 (1928) 13424
52 week clinical data 0.22 (0.17) 2309 (1508) 10564
Liraglutide delayed by 1 year 0.12 (0.16) 2340 (1581) 19960 - - -
Liraglutide 1.2 mg cost &:
100% of 1.8 mg efficacy - - - 0.19 (0.16) −1473 (1492) Lira. Dominant
90% of 1.8 mg efficacy - - - 0.14 (0.15) −1016 (1500) Lira. Dominant
80% of 1.8 mg efficacy - - - 0.08 (0.15) −625 (1613) Lira. Dominant
70% of 1.8 mg efficacy - - - 0.02 (0.15) −126 (1525) Lira. Dominant
Data are mean (SD). QALY = quality-adjusted life year; € = 2013 Euros; ICER = incremental cost-effectiveness ratio; HbA1c = glycated haemoglobin; UKPDS = United
Kingdom Prospective Diabetes Study; SBP = systolic blood pressure; BMI = body mass index; Hypo = hypoglycaemic event; Lira = Liraglutide.
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http://www.biomedcentral.com/1472-6963/14/419treatment to be associated with an ICER of £9851/QALY
gained. Similarly, in Spain [31] liraglutide 1.2 mg resulted
in an ICER of €13266/QALY gained. Considering the lira-
glutide 1.8 mg versus exenatide (BID) comparison, theformer treatment exhibited an ICER of $40282/QALY
gained in the US payer setting [32], while in the European
Union setting (in six different countries: Switzerland,
Denmark, Norway, Finland, The Netherlands, and Austria)
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€6902 and €13546/QALY gained [33]. Overall, the results
across the various country-specific settings are in line with
results reported here and no meaningful deviations were
traced.
In general, the sensitivity analyses indicated that these
results were robust under a range of assumptions. In the
liraglutide against sitagliptin comparison, the key drivers
of cost-effectiveness were HbA1c and weight (to a lesser
extent), with only small impact from the rest of the
physiological parameters. These findings, are in accord-
ance with previous cost-effectiveness studies [23,31], as
well as the higher efficacy of liraglutide versus sitagliptin
in decreasing HbA1c and weight reported in the 1860
clinical study. In to the liraglutide against exenatide
comparison, HbA1c was the most important driver of
cost-effectiveness in line with previous literature [32,33],
with only small effects from the other physiological
parameters. This is a quite reassuring remark, since the
HbA1c effect was the primary efficacy endpoint of the
LEAD 6 trial and benefit in HbA1c related with liraglu-
tide was shown to be significantly greater than that
observed with exenatide. In light of both treatment com-
parisons, remarkably lower ICERs were yielded in case
of 3 year treatment duration, as the accumulated effect-
iveness of each therapy reached almost at the same level
of the base case, whereas the respective direct total costs
incurred by patients were significantly lower given the
shortening of drugs usage duration. This outcome,
indeed, is quite interesting and may be in need of further
investigation at a later date. In respect of time horizon
assumptions, the cost-effectiveness results were quite
sensitive (upward trend) to deviations from baseline
model timeframe, most probably on grounds of the con-
siderable lag time in the manifestation of diabetes com-
plications after long periods of poor glycaemic control.
The shortening of simulation time horizons to this
extent halters the emergence of any relative differences
in complication rates. Additionally, when Greek cohort
data geared higher ICERs were estimated. This could be
attributed to the fact that the Greek intervention cohort
might have been in a more advanced stage of disease
progression, since the mean age and duration of diabetes
were significantly higher than in the 1860 and LEAD-6
trial cohorts, and so did some mean baseline biochem-
ical risk characteristics and proportions with comorbid-
ity complications (Table 1). In this respect, the aging
process alongside with the overall worse baseline cohort
features likely had more severe consequences in patients’
health during model simulations, resulting, thus, in much
lower accumulated QALYs considering all treatment com-
parators. Nonetheless, it should be stressed that the ICER
values were found to be below the threshold of €34000
per QALY gained and, therefore, liraglutide treatmentcontinued to be a cost-effective option. Furthermore,
delaying liraglutide 1.2 mg treatment by 1 year was an un-
favourable option (increased ICER) similar to findings in a
previous study carried out in Spain [31]. The displayed
liraglutide 1.2 mg dominance over exenatide was expected
given the current clinical and cost data.
Several potential limitations to this study should be con-
sidered. First, the generalizability of the present findings is
constrained to those patients with relatively advanced
disease (Table 1), who were insufficiently controlled with
OADs. Moreover, based on three recent studies [34-36]
and clinical experts opinion it was assumed that HbA1c
could be maintained over time with adequate pharmaco-
therapy, in both insulin and non-insulin users, in contrast
to the UKPDS progression equation according to which,
HbA1c levels gradually increase as beta-cell function
diminishes over time [10]. In this regard, the results of the
present study are fully related to this assumption in an at-
tempt to best reflect current clinical practice. Additionally,
like all models used to gauge the long-term outcomes of
patients with T2DM, this model makes long-term projec-
tions of outcomes relied upon the findings of short-term
studies. Nevertheless, the CDM has been validated against
real life data demonstrating a reliable predicting analysis
behaviour [9].
Conclusions
To conclude, the present economic evaluation suggests
that, under a willingness-to-pay threshold of €34000 per
QALY gained, liraglutide was estimated to be a highly
cost-effective option for the treatment of T2DM in a
Greek setting.
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